Bextra Relaunch Plan Could Include Weekly Monitoring, Pfizer CEO Says

Pfizer is focusing on finalizing Celebrex relabeling and safety study, but plans to turn attention to Bextra "once the dust settles," McKinnell says. Potential risk management plan for the COX-2 inhibitor could include weekly doctor's visits to monitor skin rash risk during first month of treatment.